COVID-19 Rapid Response Innovation Project
A test to measure the prognosis of COVID-19 patients entering hospital
The challenge
As doctors try to deal with COVID-19, they need to understand each patient’s prognosis and what kind of treatment that patient can handle. Without more information about these parameters, doctors cannot make the best decisions about managing their patients’ treatment.
The solution
The ProCop project aims to develop and validate a new blood-based score for COVID-19 to help determine: 1) the severity of a patient’s condition and their prognosis; 2) the patient’s likelihood of developing a drug-induced-liver-injury due to COVID-19 medication. This innovative and simple-to-use severity score comprises a blood-sample followed by an automated algorithmic computation. The algorithm takes into account the patient’s age, gender and the results of five routine assays to test for proteins and enzymes in the blood. The resulting prognosis will be available within two hours.
Expected impact
The ProCop Severity Score will give doctors information they need to tailor the treatment and management of each patient. Hospitals can use the predictions to assess the resources they will need to treat their patients in the next 14 days.
All Partners
EIT Health Partner
- Assistance Publique – Hôpitaux de Paris
External partner
- BioPredictive
EIT Health Partner
CLC/InnoStars: France
Partner classification: Tech Transfer, Clusters, Other NGOs, Hospital / University Hospital
Partner type: Core Partner
We are a teaching hospital with a European dimension globally recognized. Our 39 hospitals attended each year 8 million sick people: consultation in emergency hospitalizations during scheduled or home hospitalization. We provide a public health service for all, 24/24, and it is for us both a duty and pride.
Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris, 1 Avenue Claude Vellefaux, 75010 Paris, France